Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
← catalyst calendarSponsored by Grace Therapeutics Inc. (industry) · GRCE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
100estimated
Sites
22
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-20 | actual | When the study began enrolling |
| Primary completion | Dec 2024 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2024 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-10-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions
- Drug: GTX-104
- Drug: Nimotop 30 MG Oral Capsule
Primary outcome
what the primary-completion date above is the date OFIncidence (% or proportion) of subjects with at least one episode of clinically significant hypotension with a reasonable possibility that GTX-104/oral nimodipine caused the event, according to the Endpoint Adjudication Committee.
measured 90 days
Publications
- PMID 39875683 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GRCE's whole pipeline · Catalyst calendar · Every registered study · What changed